Graves' disease, Multiple sclerosis, Myasthenia gravis, Rheumatoid arthritis, Pernicious anemia and Systemic lupus erythematosus are the most prevalent types of autoimmune disorders. The prevalence of autoimmune diseases is high in women than in men, which results from the influence of estrogen on immune system. Asia pacific autoimmune treatment market is rising with promising CAGR and large market value is attributed to key clinical conditions as rheumatoid arthritis (RA) and multiple sclerosis (MS). Over the past few years the prevalence of some clinical conditions such as type-1 diabetes and celiac disease is high in Asia pacific region which is the most critical driver for the Asia pacific autoimmune disorders treatment market. Additionally, majority of the manufacturers in Asia pacific region have focused on developing generic forms of biological drugs which are popular as a first line of treatment. Rising healthcare expenditure and patient awareness have also potentiated the growth of Asia pacific autoimmune disorders treatment market. However, restraints explicitly include high cost of therapy, no absolute cure and unsafe nature of biologics. All these factors contribute to slow increase in patient volume. Protein based drugs and use of safe & efficacious biologics and increasing investment from multinationals in Asia pacific region open new avenues for Asia pacific autoimmune disorders treatment market.
The Asia pacific autoimmune disorders treatment market is segmented on the basis of products, technology, application, service and geography. Based on product types, the market is sub-categorized as therapeutic drug products and therapeutic equipment. Product market is dominated by the drug products that include Immunosuppressant, DMARDs, NSAIDs, Anti-inflammatory drugs, Anti-cancer drugs, Anti- malarial drugs and Biologics. Presently, biologics, combined with immunotherapy and cancer medicines, have gained significant market share. Based on technology, the Asia pacific autoimmune disorders treatment market is segmented into Bridge therapy, Recombinant technology, fecal bacteriotherapy, Phototherapy and other technologies. The technologies used to treat Rheumatoid arthritis contribute to a larger share as compared to other clinical conditions of autoimmune diseases. Based on applications, the Asia pacific autoimmune treatment market is segmented into systemic autoimmune diseases (involve several organs of the body) and localized autoimmune diseases (involve single organ). Rheumatoid arthritis and multiple sclerosis dominate the market in systemic and localized application types, respectively. These two diseases, along with Psoriasis, account for notable market sales. Services market for autoimmune disorders treatment includes consultation & diagnosis, therapy & monitoring and drug development services. The Asia pacific autoimmune disorders treatment market is segmented by geography into China, Japan, India, Australia and others. India and China are emerging market for autoimmune disease treatment due to high unmet medical needs, improving healthcare infrastructure and rising healthcare expenditure. These two countries are expected to witness a fastest growth for diagnosis and treatment of autoimmune disorders. This growth would be primarily driven by rising edge of biosimilars and generic drugs in China and India.
Key market players of Asia pacific autoimmune disorders treatment market includes, Abbott Laboratories, Roche Diagnostics, Siemens Healthcare, Johnson & Johnson, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Sanofi, Merck, and Pfizer Inc. Recently, Abbott has announced Thyroid Awareness Initiative in India, which aimed at greater understanding of thyroid disorder that would amplify the access to its diagnosis.
KEY TAKE AWAYS
- Deep-dive analysis of different segment as applications, products, services, technologies and geography for Asia Pacific autoimmune disorders treatment market provides the key insights of multiple segments
- In-depth analysis of various geographies would give an understanding of the trends in various regions so that companies can make country specific plans
- The projections in the report are made by analyzing the current market trends and future market potential for the period of 2014-2020 in terms of value
- Comprehensive assessment of Asia pacific autoimmune disorders treatment market including drivers, restrains and opportunities would assist professionals to understand the market behavior
- Competitive landscape includes the leaders for within Asia pacific region for the autoimmune treatment market with key strategies adopted by them to achieve high monetary value
- Market attractiveness analysis for the Asia Pacific autoimmune treatment market provides strategic assistance to decision makers
- Ease of doing business analysis should help in making strategic business decisions
AUTOIMMUNE DISORDERS TREATMENT MARKET KEY SEGMENTS
The Asia pacific autoimmune disorders treatment market is segmented in to five categories such as, product, technology, application, service and geography.
BY PRODUCT TYPE
- Therapeutic drug Products
- Anti-inflammatory drugs
- Anti-cancer drugs
- Anti- malarial drugs
- Therapeutic equipment
- Diagnostic equipment
- Therapeutic and monitoring equipment
- Bridge therapy
- Recombinant technology
- Fecal bacteriotherapy
- Hematopoietic stem-cell transplantation
- Helminthic therapy
- Activation-induced assays
- Cytometry by time-of-flight mass spectrometry
- Systemic autoimmune diseases (involve several organs of the body)
- Localized autoimmune diseases (involve single organ)
- Consultation & Diagnosis
- Therapy & Monitoring
- Drug Development
"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."